RU2470016C2 - Производное бипиразола - Google Patents
Производное бипиразола Download PDFInfo
- Publication number
- RU2470016C2 RU2470016C2 RU2010119648/04A RU2010119648A RU2470016C2 RU 2470016 C2 RU2470016 C2 RU 2470016C2 RU 2010119648/04 A RU2010119648/04 A RU 2010119648/04A RU 2010119648 A RU2010119648 A RU 2010119648A RU 2470016 C2 RU2470016 C2 RU 2470016C2
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- bipyrazolyl
- hydroxyadamantan
- obesity
- butyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Изобретение относится к фармацевтической композиции для лечения диабета, ожирения или метаболического синдрома, которая включает терапевтически эффективное количество (5-гидроксиадамантан-2-ил)амида транс-2'-трет-бутил-2'H-[1,3']бипиразолил-4'-карбоновой кислоты или его фармацевтически приемлемых солей, и фармацевтически приемлемый носитель. Изобретение также относится и к применению вышеназванного соединения для приготовления лекарственного средства, предназначенного для лечения указанных выше заболеваний. 2 н.п. ф-лы, 1 табл., 99 пр.
Description
Claims (2)
1. Фармацевтическая композиция для лечения диабета, ожирения или метаболического синдрома, включающая терапевтически эффективное количество (5-гидроксиадамантан-2-ил)амида транс-2'-трет-бутил-2'H-[1,3']бипиразолил-4'-карбоновой кислоты или его фармацевтически приемлемых солей, и фармацевтически приемлемый носитель.
2. Применение (5-гидроксиадамантан-2-ил)амида транс-2'-трет-бутил-2'H-[1,3']бипиразолил-4'-карбоновой кислоты для приготовления лекарственных средств, предназначенных для лечения диабета, ожирения или метаболического синдрома.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78483106P | 2006-03-22 | 2006-03-22 | |
US60/784,831 | 2006-03-22 | ||
US87527406P | 2006-12-15 | 2006-12-15 | |
US60/875,274 | 2006-12-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008141434/04A Division RU2402517C2 (ru) | 2006-03-22 | 2007-03-12 | Пиразолы в качестве ингибиторов 11-бета-hsd-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010119648A RU2010119648A (ru) | 2011-11-27 |
RU2470016C2 true RU2470016C2 (ru) | 2012-12-20 |
Family
ID=38430507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010119648/04A RU2470016C2 (ru) | 2006-03-22 | 2007-03-12 | Производное бипиразола |
RU2008141434/04A RU2402517C2 (ru) | 2006-03-22 | 2007-03-12 | Пиразолы в качестве ингибиторов 11-бета-hsd-1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008141434/04A RU2402517C2 (ru) | 2006-03-22 | 2007-03-12 | Пиразолы в качестве ингибиторов 11-бета-hsd-1 |
Country Status (30)
Country | Link |
---|---|
US (1) | US7728029B2 (ru) |
EP (2) | EP1999114B1 (ru) |
JP (1) | JP5031817B2 (ru) |
KR (2) | KR20110007258A (ru) |
CN (1) | CN101405270B (ru) |
AR (1) | AR059983A1 (ru) |
AU (1) | AU2007228887B2 (ru) |
BR (1) | BRPI0708974A2 (ru) |
CA (1) | CA2645856C (ru) |
CR (1) | CR10288A (ru) |
DK (1) | DK1999114T3 (ru) |
EC (1) | ECSP088747A (ru) |
ES (1) | ES2548002T3 (ru) |
HK (1) | HK1130780A1 (ru) |
HR (1) | HRP20151078T1 (ru) |
HU (1) | HUE026011T2 (ru) |
IL (1) | IL193900A (ru) |
MA (1) | MA30344B1 (ru) |
MX (1) | MX2008012017A (ru) |
MY (1) | MY149622A (ru) |
NO (1) | NO341746B1 (ru) |
NZ (1) | NZ570973A (ru) |
PL (1) | PL1999114T3 (ru) |
PT (1) | PT1999114E (ru) |
RS (1) | RS54216B1 (ru) |
RU (2) | RU2470016C2 (ru) |
SG (1) | SG155961A1 (ru) |
SI (1) | SI1999114T1 (ru) |
TW (2) | TW201103916A (ru) |
WO (1) | WO2007107470A2 (ru) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2630665C (en) | 2005-11-21 | 2011-03-15 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i |
EP2610241A1 (en) * | 2006-11-02 | 2013-07-03 | Shionogi & Co., Ltd. | Process for production of hydroxyadamantaneamine |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
US20100144717A1 (en) * | 2006-12-15 | 2010-06-10 | Janelle Comita-Prevoir | 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
CN103288738B (zh) * | 2007-05-18 | 2016-03-16 | 盐野义制药株式会社 | 具有11β-羟基类固醇脱氢酶I型抑制活性的含氮杂环衍生物 |
RU2440989C2 (ru) * | 2007-07-17 | 2012-01-27 | Ф.Хоффманн-Ля Рош Аг | ИНГИБИТОРЫ 11β-ГИДРОКСИСТЕРОИДНОЙ ДЕГИДРОГЕНАЗЫ |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2072497A1 (de) * | 2007-12-21 | 2009-06-24 | Bayer CropScience AG | Verfahren zum Herstellen von 2-Fluoracyl-3-amino-acrylsäure-Derivaten |
US7951833B2 (en) * | 2008-02-04 | 2011-05-31 | Astrazeneca Ab | Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471 |
CN102300851A (zh) * | 2009-01-30 | 2011-12-28 | 阿斯利康(瑞典)有限公司 | 制备含羧基的吡唑酰氨基化合物597的新方法 |
EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
US8871208B2 (en) * | 2009-12-04 | 2014-10-28 | Abbvie Inc. | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof |
EP2518051A4 (en) * | 2009-12-22 | 2013-10-16 | Shionogi & Co | ADAMANTANAMINE DERIVATIVE |
CN102127583A (zh) * | 2010-01-19 | 2011-07-20 | 上海博康精细化工有限公司 | 一种反式对氨基金刚烷醇的制备方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8680098B2 (en) | 2010-03-05 | 2014-03-25 | Janssen Pharmaceutica, Nv | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
CN103209957A (zh) | 2010-08-09 | 2013-07-17 | 盐野义制药株式会社 | 氨基金刚烷氨基甲酸酯衍生物的制备方法 |
JP5605104B2 (ja) * | 2010-09-10 | 2014-10-15 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8471027B2 (en) | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
CH706864B1 (de) | 2011-06-22 | 2016-03-31 | Central Glass Co Ltd | Verfahren zur Herstellung einer Pyrazol-Verbindung. |
JP5915004B2 (ja) * | 2011-06-22 | 2016-05-11 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
JP2013023476A (ja) * | 2011-07-22 | 2013-02-04 | Sagami Chemical Research Institute | 5−フルオロ−1h−ピラゾール−4−カルボン酸類の製造方法 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
AR089656A1 (es) | 2011-11-30 | 2014-09-10 | Bayer Ip Gmbh | Derivados de n-bicicloalquil- y n-tricicloalquil-(tio)-carboxamida fungicidas |
CN102633659B (zh) * | 2012-02-23 | 2013-12-04 | 浙江普洛康裕制药有限公司 | 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 |
NO2953942T3 (ru) | 2013-02-06 | 2018-03-24 | ||
KR101763284B1 (ko) | 2013-07-24 | 2017-07-31 | 볼보 컨스트럭션 이큅먼트 에이비 | 건설기계용 유압회로 |
EP3083566B1 (en) * | 2013-11-27 | 2022-12-21 | Bayer Animal Health GmbH | Process for the preparation of 5-fluoro-1h-pyrazoles |
MX2016006977A (es) | 2013-11-27 | 2016-09-07 | Bayer Cropscience Ag | Proceso para la preparacion de 5-fluoro-1h-pirazoles. |
MX2016008653A (es) | 2014-01-03 | 2016-09-26 | Bayer Animal Health Gmbh | Nuevas pirazolil-heteroarilamidas como agentes plaguicidas. |
CN105315284A (zh) * | 2014-07-23 | 2016-02-10 | 上海医药工业研究院 | 阿拉格列汀中间体的制备方法 |
CN104961698A (zh) * | 2015-07-13 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 末端硝基取代的三氮唑亚砜类化合物、其制备方法及其用途 |
KR101759874B1 (ko) * | 2015-08-07 | 2017-07-21 | 코스맥스 주식회사 | 11β-hydroxysteroid dehydrogenase type 1의 활성을 저해하는 화합물을 포함하는 화장료 조성물 또는 피부 외용제 조성물 |
EP3976599A1 (en) * | 2019-05-24 | 2022-04-06 | Fmc Corporation | Pyrazole-substituted pyrrolidinones as herbicides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089896A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
RU2005122936A (ru) * | 2002-12-20 | 2006-01-20 | Мерк энд Ко., Инк. (US) | Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1 |
RU2381217C2 (ru) * | 2005-04-05 | 2010-02-10 | Ф.Хоффман-Ля Рош Аг | Пиразолы |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH307629A (de) | 1952-05-23 | 1955-06-15 | Ag J R Geigy | Verfahren zur Herstellung eines monosubstituierten Hydrazins. |
DE2635841C2 (de) | 1976-08-10 | 1983-02-24 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur Herstellung von Alkoxymethylenmalonsäurenitrilen |
US4620865A (en) | 1983-11-07 | 1986-11-04 | Eli Lilly And Company | Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides |
US4742074A (en) | 1984-10-29 | 1988-05-03 | Sumitomo Chemical Company, Limited | Pyrazolecarboxamide derivative and fungicide containing it as active ingredient |
US4792565A (en) | 1986-04-24 | 1988-12-20 | Mitsui Toatsu Chemicals, Inc. | Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds |
DE4010797A1 (de) | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
US6020121A (en) | 1995-09-29 | 2000-02-01 | Microcide Pharmaceuticals, Inc. | Inhibitors of regulatory pathways |
DE19615976A1 (de) | 1996-04-22 | 1997-10-23 | Basf Ag | Mittel und Verfahren zur Bekämpfung von Schadpilzen |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
JP4398088B2 (ja) | 1997-12-18 | 2010-01-13 | ビーエーエスエフ ソシエタス・ヨーロピア | アミド化合物及びモルホリン又はピペリジン誘導体を基礎とする殺菌剤混合物 |
WO1999067235A1 (fr) | 1998-06-25 | 1999-12-29 | Sumitomo Pharmaceuticals Co., Ltd. | Composes cycliques a cinq elements |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
DE19853827A1 (de) | 1998-11-21 | 2000-05-25 | Aventis Cropscience Gmbh | Kombinationen aus Herbiziden und Safenern |
US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
IL136360A (en) | 1999-06-18 | 2004-08-31 | Mitsui Chemicals Inc | History 5 - Aminopyrazole-4 - Carboxylate and processes for their preparation |
KR100743262B1 (ko) | 1999-07-20 | 2007-07-27 | 다우 아그로사이언시즈 엘엘씨 | 살균성 헤테로고리 방향족 아미드 및 그 조성물, 사용 및제조방법 |
WO2001014339A2 (en) | 1999-08-20 | 2001-03-01 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
AU780572B2 (en) | 1999-10-18 | 2005-04-07 | University Of Connecticut, The | Pyrazole derivatives as cannabinoid receptor antagonists |
US6096898A (en) | 1999-10-22 | 2000-08-01 | Dow Agrosciences Llc | One pot synthesis of 1,2,4-triazoles |
US6569885B1 (en) | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
JP2002003410A (ja) | 2000-06-27 | 2002-01-09 | Fuji Photo Film Co Ltd | 芳香族ハロゲン化物の製造方法。 |
WO2002044133A1 (en) | 2000-11-28 | 2002-06-06 | Pfizer Products Inc. | Preparation of sodium-hydrogen exchanger type-1 inhibitors |
PE20020870A1 (es) | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
WO2003028641A2 (en) | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
CA2465207C (en) | 2001-11-01 | 2011-01-04 | Icagen, Inc. | Pyrazole-amides and -sulfonamides |
DE10161978A1 (de) | 2001-12-17 | 2003-06-26 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenacyl-3-amino-acrylsäure-derivate |
MXPA04004685A (es) | 2001-12-19 | 2004-08-12 | Pfizer Prod Inc | Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno. |
US6818772B2 (en) | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
WO2003070244A1 (en) | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagonist of melanin concentrating hormone and their uses |
US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
EP1388535A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
CN1703395A (zh) | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
KR100729878B1 (ko) | 2003-02-17 | 2007-06-18 | 에프. 호프만-라 로슈 아게 | 피페리딘-벤젠설폰아마이드 유도체 |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
PL1618092T3 (pl) | 2003-05-01 | 2011-02-28 | Bristol Myers Squibb Co | Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
WO2005000793A1 (ja) | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2位置換シクロアルキルカルボン酸誘導体 |
CA2526455C (en) | 2003-06-26 | 2012-10-09 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
CA2534221A1 (en) | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
CA2535265C (en) | 2003-08-22 | 2014-01-28 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
US7750160B2 (en) | 2003-11-13 | 2010-07-06 | Ambit Biosciences Corporation | Isoxazolyl urea derivatives as kinase modulators |
CN101367748B (zh) | 2004-01-28 | 2014-03-12 | 三井化学株式会社 | 酰胺衍生物及其制备方法和作为杀虫剂的使用方法 |
CN1976905A (zh) | 2004-03-30 | 2007-06-06 | 大正制药株式会社 | 嘧啶衍生物以及与其应用有关的治疗方法 |
DE102004023635A1 (de) | 2004-05-10 | 2006-04-13 | Grünenthal GmbH | Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate |
WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
GB0417910D0 (en) | 2004-08-11 | 2004-09-15 | Novartis Ag | Organic compounds |
WO2006031806A2 (en) | 2004-09-10 | 2006-03-23 | Atherogenics, Inc. | 2-thiopyrimidinones as therapeutic agents |
US20080090863A1 (en) | 2004-09-30 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor |
GB0506133D0 (en) | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
CA2630665C (en) * | 2005-11-21 | 2011-03-15 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i |
-
2007
- 2007-03-12 RU RU2010119648/04A patent/RU2470016C2/ru not_active IP Right Cessation
- 2007-03-12 PT PT77267839T patent/PT1999114E/pt unknown
- 2007-03-12 RU RU2008141434/04A patent/RU2402517C2/ru not_active IP Right Cessation
- 2007-03-12 MX MX2008012017A patent/MX2008012017A/es active IP Right Grant
- 2007-03-12 KR KR1020107029250A patent/KR20110007258A/ko not_active Application Discontinuation
- 2007-03-12 JP JP2009500818A patent/JP5031817B2/ja not_active Expired - Fee Related
- 2007-03-12 ES ES07726783.9T patent/ES2548002T3/es active Active
- 2007-03-12 PL PL07726783T patent/PL1999114T3/pl unknown
- 2007-03-12 NZ NZ570973A patent/NZ570973A/en not_active IP Right Cessation
- 2007-03-12 AU AU2007228887A patent/AU2007228887B2/en not_active Ceased
- 2007-03-12 HU HUE07726783A patent/HUE026011T2/en unknown
- 2007-03-12 CA CA2645856A patent/CA2645856C/en not_active Expired - Fee Related
- 2007-03-12 BR BRPI0708974-0A patent/BRPI0708974A2/pt not_active Application Discontinuation
- 2007-03-12 SG SG200906335-5A patent/SG155961A1/en unknown
- 2007-03-12 DK DK07726783.9T patent/DK1999114T3/en active
- 2007-03-12 CN CN2007800097486A patent/CN101405270B/zh not_active Expired - Fee Related
- 2007-03-12 EP EP07726783.9A patent/EP1999114B1/en active Active
- 2007-03-12 RS RS20150580A patent/RS54216B1/en unknown
- 2007-03-12 WO PCT/EP2007/052269 patent/WO2007107470A2/en active Application Filing
- 2007-03-12 EP EP10175020A patent/EP2295411A1/en not_active Withdrawn
- 2007-03-12 MY MYPI20083704A patent/MY149622A/en unknown
- 2007-03-12 KR KR1020087025604A patent/KR101077366B1/ko not_active IP Right Cessation
- 2007-03-12 SI SI200731685T patent/SI1999114T1/sl unknown
- 2007-03-14 US US11/717,996 patent/US7728029B2/en not_active Expired - Fee Related
- 2007-03-19 TW TW099133403A patent/TW201103916A/zh unknown
- 2007-03-19 TW TW096109371A patent/TWI351403B/zh not_active IP Right Cessation
- 2007-03-20 AR ARP070101126A patent/AR059983A1/es not_active Application Discontinuation
-
2008
- 2008-09-04 IL IL193900A patent/IL193900A/en not_active IP Right Cessation
- 2008-09-09 NO NO20083863A patent/NO341746B1/no not_active IP Right Cessation
- 2008-09-16 CR CR10288A patent/CR10288A/es unknown
- 2008-09-18 EC EC2008008747A patent/ECSP088747A/es unknown
- 2008-10-20 MA MA31307A patent/MA30344B1/fr unknown
-
2009
- 2009-09-24 HK HK09108733.6A patent/HK1130780A1/xx not_active IP Right Cessation
-
2015
- 2015-10-12 HR HRP20151078TT patent/HRP20151078T1/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2005122936A (ru) * | 2002-12-20 | 2006-01-20 | Мерк энд Ко., Инк. (US) | Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1 |
WO2004089896A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
RU2381217C2 (ru) * | 2005-04-05 | 2010-02-10 | Ф.Хоффман-Ля Рош Аг | Пиразолы |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2470016C2 (ru) | Производное бипиразола | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
JP2009500443A5 (ru) | ||
RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
WO2008027350A3 (en) | Acetaminophen pharmaceutical compositions | |
EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
WO2006131923A3 (en) | Novel salts of conjugated psychotropic drugs and processes of preparing same | |
WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
JP2011503044A5 (ru) | ||
AR057904A1 (es) | Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide | |
JP2013541583A5 (ru) | ||
WO2001047913A3 (de) | Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung | |
NZ591408A (en) | Paracetamol and Calcium carbonate composition | |
JP2010500284A5 (ru) | ||
RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190313 |